Shenzhen Boya Ganzi Pharmaceutical

Shenzhen Boya Ganzi Pharmaceutical is a specialized pharmaceutical company based in China that serves as the chemical drug research and manufacturing arm of the Boya Bio-Pharmaceutical Group. The company focuses primarily on the development of therapies for liver diseases, with a core portfolio centered on hepatology and anti-infectives. Its flagship products include Entecavir for the treatment of chronic Hepatitis B and Ademetionine 1,4-Butanedisulfonate for intrahepatic cholestasis. Following the acquisition of its parent company by China Resources Pharmaceutical Group, Boya Ganzi operates within a large-scale integrated healthcare network, leveraging extensive distribution channels across the Chinese market.